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experiments in Fig. 5, the cultured microglia (see Supplementary Figure) that had been
preincubated with or without ATP (50 mM) were injected intrathecally in normal rats (see
Supplementary Methods for full details).
Immunohistochemistry
Transverse L5 spinal cord sections (30 mm) were cut and processed for
immunohistochemistry with anti-P2X4R antibody (Alomone). Identification of the type
of P2X4R-positive cells was performed with the following markers: for microglia, OX42
(Chemicon) and iba1 (a gift from S. Kohsaka); for astrocytes, GFAP (Boehringer
Mannheim); for spinal cord neurons, NeuN (Chemicon) and MAP2 (Chemicon). To
assess immunofluorescence staining of cells quantitatively, we measured the
immunofluorescence intensity of the P2X4R or OX42 as the average pixel intensity within
each cell (see also Supplementary Methods).
Western blotting
Western blot analysis of P2X4R expression in the membrane fraction from L4–L6 spinal
cord was performed with anti-P2X4R polyclonal antibody (Oncogene) as described in
detail in the Supplementary Methods.
Microglial culture
Rat primary cultured microglia were prepared in accordance with the method described
previously28. In brief, mixed glial culture was prepared from neonatal Wistar rats and
maintained for 10–16 days in DMEM medium with 10% fetal bovine serum. Immediately
before experiments, microglia were collected by a gentle shake as the floating cells over the
mixed glial culture. The microglia were transferred to coverslips or to Eppendorf tubes for
subsequent intrathecal administration.
Statistics
Statistical analyses of the results were made with Student’s t-test, Student’s paired t-test or
the Mann–Whitney U-test.
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Amyloid diseases are characterized by an aberrant assembly of a
specific protein or protein fragment into fibrils and plaques that
are deposited in various organs and tissues1–3, often with serious
pathological consequences. Non-neuropathic systemic amyloi-
dosis4–6 is associated with single point mutations in the gene
coding for human lysozyme. Here we report that a single-domain
fragment of a camelid antibody7–9 raised against wild-type
human lysozyme inhibits the in vitro aggregation of its amyloi-
dogenic variant, D67H. Our structural studies reveal that the
epitope includes neither the site of mutation nor most residues in
the region of the protein structure that is destabilized by the
mutation. Instead, the binding of the antibody fragment achieves
its effect by restoring the structural cooperativity characteristic
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of the wild-type protein. This appears to occur at least in part
through the transmission of long-range conformational effects to
the interface between the two structural domains of the protein.
Thus, reducing the ability of an amyloidogenic protein to form
partly unfolded species can be an effective method of preventing
its aggregation, suggesting approaches to the rational design of
therapeutic agents directed against protein deposition diseases.
Four mutations in the lysozyme gene (I56T, F57I, W74R, and
D67H) have so far been identified in connection with amyloid
disease4–6. The ability of the lysozyme variants studied in detail
(I56T and D67H) to form amyloid deposits has been attributed
primarily to their reduced stability relative to the wild-type protein,
allowing transient unfolding of a local region of structure under
physiologically relevant conditions10,11. The formation of partly
structured species through this locally cooperative unfolding pro-
cess appears to be the critical event that triggers the aggregation
process and ultimately leads to the formation of amyloid fibrils and
the onset of disease11.
The use of specific antibodies is a promising strategy for inhibit-
ing and even reversing in vitro and in vivo fibril formation by
amyloidogenic peptides or proteins12–14. We focus here on the
interaction of cAb-HuL6 (ref. 7), a fragment from a ‘heavy-chain’
camel antibody with high specificity for native human lysozyme and
its amyloidogenic variants. Because antibodies derived from came-
lids (camels, dromedaries and llamas) are devoid of the light chains
of conventional antibodies, their antigen binding sites are limited to
single domains, referred to as VHHs
8. Such domains have very
favourable properties7–9 for biophysical studies, including small size
and high solubility and stability.
To investigate the effects of the antibody fragment on fibril
formation, conditions were selected (48 8C, pH 5.5, 3 M urea)
under which the D67H variant readily aggregates in vitro while
the antibody fragment remains stable and is still able to bind tightly
to native lysozyme. In the absence of the antibody fragment, the
data show that the D67H variant readily aggregates (Fig. 1a). The
kinetics follow a sigmoidal curve consistent with the nucleation-
dependent growth model that has been suggested as a common
mechanism of fibril formation15. After incubation for 6 h, the
protein solution was passed through a 0.22 mm filter and examined
by SDS–polyacrylamide gel electrophoresis (SDS–PAGE). No pro-
tein could be detected on the gel (Fig. 1b, lane 4), indicating that
virtually all the D67H protein had aggregated to form species too
large to pass through the filter; the slight increase in light scattering
observed over longer incubation times (6–15 h, Fig. 1a) is likely to
result from the organization of the aggregates into higher-order
structures. In contrast, when wild-type lysozyme was incubated
under the same conditions, it remained almost completely soluble
even after 20 h (Fig. 1a, b).
The aggregated species formed by the D67H variant under the
conditions described above bind Congo red, producing the charac-
teristic red shift in the absorption spectrum of the dye typically
observed during amyloid fibril formation16. The presence of large
quantities of fibrillar material was unambiguously confirmed by
negative-stain transmission electron microscopy (TEM) (Fig. 1c).
The structures observed include some well-resolved isolated fibrils
(approximately 6 nm in diameter) although most fibrils appear to
be incorporated into large bundles (100–400 nm in diameter). Such
structures have previously been observed with a variety of other
amyloidogenic proteins17, including the I56T variant of human
lysozyme after incubation at pH 2 and 37 8C (ref. 18). Moreover, the
X-ray fibre diffraction pattern of the fibrils (Fig. 1d) shows a
dominant meridional reflection at 4.7 Å and an equatorial reflection
at 10.4 Å, features characteristic of amyloid fibrils as a consequence
of their cross-b structure19.
When the D67H protein was incubated in the presence of an
equimolar amount of the antibody fragment, no significant changes
in light scattering were detectable after 6 h of incubation (Fig. 1a),
and after passage of the solution through a 0.22 mm filter, SDS–
PAGE confirmed that virtually all of the D67H protein incubated
with the antibody fragment remained in solution (Fig. 1b, lane 6).
Finally, TEM analysis showed no evidence for the presence of
amyloid fibrils or other aggregates. Thus, in the presence of an
equimolar quantity of antibody fragment, the D67H variant
behaves very similarly to the wild-type protein in the absence of
the antibody fragment. Moreover, the rate of aggregation of the
D67H protein in the presence of the antibody fragment can be
estimated to be reduced by a factor of at least 100 relative to that in
its absence. In the presence of a sub-stoichiometric amount of the
antibody fragment (a D67H:cAb-HuL6 ratio of 1:0.5), the initial
rate of aggregation of the D67H variant was reduced by a factor of
approximately 3 (Fig. 1a). Then, after about 50% of the protein had
formed aggregates, the remainder aggregated even more slowly,
presumably at a rate limited by the rate of dissociation of the D67H
protein from the complex. These observations provide clear evi-
dence that the binding of the antibody fragment to the variant




Figure 1 Effect of cAb-HuL6 on the aggregation of D67H lysozyme. a, Time course of the
aggregation of D67H lysozyme in the absence (blue) and presence of the antibody
fragment (D67H:cAb-HuL6 1:1 (green), D67H:cAb-HuL6 1:0.5 (pink)) monitored by light
scattering. Data are also shown for wild-type lysozyme in the absence of cAb-HuL6 (red).
Inset, expansion to demonstrate the lag phase at the onset of the aggregation process.
b, SDS–PAGE of protein solutions filtered through a 0.22 mm filter before incubation at
48 8C (series a) and after 6 h of incubation at 48 8C (series b). Note that the D67H
lysozyme and the cAb-HuL6 have similar relative molecular masses (14,715 and 14,220,
respectively) and thus they migrate in closely similar position in lanes 5 and 6. The
comparable intensities of the bands before and after heating suggest that both proteins
remain soluble after treatment; this result was confirmed by measuring the protein
concentration in the supernatant, using the BCA assay. c, Representative image of fibrils
formed from the D67H variant produced by TEM. d, X-ray fibre diffraction pattern of the
fibrils showing a prominent meridional reflection at 4.7 Å and an equatorial reflection at
10.4 Å, features typical of amyloid fibrils as a result of their cross-b structure. The
additional equatorial reflections observed at 7.8 Å and 13.8 Å may arise from the
superposition of interference functions as a consequence of the close packing of
protofilaments19.
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Thermal denaturation experiments followed by far-ultraviolet
circular dichroism measurements under the buffer conditions in
which the uncomplexed D67H variant forms fibrils indicate that the
temperature of the mid-point of unfolding of the D67H variant
(Tm ¼ 55 ^ 1 8C) is reduced by about 10 8C compared with that of
the wild-type protein, (Tm ¼ 65 ^ 1 8C). In the presence of an
equimolar amount of the antibody fragment, however, the stability
of the variant protein is raised by about 15 8C (Tm ¼ 70 ^ 1 8C).
Within the complex, therefore, the thermal stability of the D67H
lysozyme is even greater than that of the wild-type protein in the
absence of the antibody fragment. Furthermore, thermally induced
denaturation of the D67H variant was observed to be associated
with a significant increase in the fluorescence intensity of 8-anilino-
1-naphthalene-sulphonic acid (ANS) at 475 nm (data not shown),
indicating that a partly unfolded intermediate species with one or
more hydrophobic regions exposed to the solvent is significantly
populated during unfolding. A similar enhancement of ANS fluor-
escence was not observed, however, in the presence of the antibody
fragment. These data suggest that in the presence of the antibody
fragment the D67H variant unfolds in a single cooperative two-state
transition.
Further insight into the dynamics and structural cooperativity of
the amyloidogenic D67H variant in the presence of the antibody
fragment was gained from hydrogen/deuterium exchange pulse-
labelling experiments analysed by mass spectrometry11. The bimo-
dal mass distribution observed with the D67H protein as exchange
takes place (Fig. 2a) is indicative of the transient cooperative
unfolding of a local region of the structure shown previously to
consist of the b-domain and the adjacent C-helix11. The time course
of the intensity of the peak corresponding to the lower mass species
in Fig. 2a provides a direct measure of the opening rate of the
cooperative fluctuation giving rise to exchange (Fig. 2a inset); the
time constant (t) of 15.3 ^ 0.6 s obtained from this analysis is
consistent with earlier data obtained at higher pH values11. Most
significantly, however, the peak that is observed at lower mass in the
absence of the antibody fragment (coloured yellow in Fig. 2a) is not
observed in the spectrum when an equimolar amount of the
antibody fragment is present (Fig. 2b). Instead, the D67H protein
gives rise to a single peak whose mass progressively decreases with
time, an observation indicative of the gradual exchange of the
various labile deuterons in the protein. Similar behaviour has
been observed with the wild-type protein in the absence of the
antibody fragment and results from amide hydrogens undergoing
exchange through highly localized independent fluctuations of the
structure11.
These observations demonstrate that, in the presence of an
equimolar amount of the antibody fragment, virtually none of the
molecules of the D67H variant undergoes even a single locally
cooperative unfolding event on the timescale of the experiment
(about 1 h). This result indicates that the frequency of such
fluctuations in the D67H variant is reduced by a factor of at least
2,000 as a result of binding to the antibody fragment. The presence
 
 
Figure 2 Electrospray mass spectra of D67H lysozyme in the absence (a) and presence
(b) of an equimolar amount of cAb-HuL6. The peaks observed in spectra of control
samples recorded after complete hydrogen–deuterium exchange are coloured black. The
peaks coloured green arise from the gradual loss of deuterium during the course of the
exchange reaction that occurs by an EX2 mechanism11. The peaks coloured yellow are
observed in the spectra of the D67H variant in the absence of the antibody fragment but
not in its presence. They result from the locally cooperative unfolding event giving rise to
exchange by an EX1 mechanism11. Note the difference in the timescale between a and b.
Inset in a, time course of the relative intensity of the lower mass species (peaks coloured
yellow) observed for the unbound D67H variant (Fig. 2a). Fitting these data to an
exponential function indicates that the time constant of the unfolding process is
15.3 ^ 0.6 s.
 
 
Figure 3 X-ray structure of wild-type human lysozyme complexed with cAb-HuL7.
a, Ribbon representation of the complex. The b-strands in cAb-HuL6 are coloured green.
The lysozyme molecule is shown in grey and the helices are labelled. The disulphide
bridges are coloured orange. b, Enlarged view of the binding interface (that is, the area in
the box in a). The side chains of residues constituting the epitope are shown in violet, light
blue and dark blue for the a-domain, C-helix and b-domain of lysozyme, respectively.
Those residues constituting the paratope are shown in yellow, pink and red, and are from
the CDR1, CDR2 and CDR3 loops of the VHH structure, respectively. The structure was
produced by using MOLMOL (ref. 30).
letters to nature
NATURE | VOL 424 | 14 AUGUST 2003 | www.nature.com/nature 785© 2003 Nature Publishing Group
of a stoichiometric amount of a VHH that does not interact with
lysozyme, cAb-R27, was found to have no effect on the dynamics of
the D67H variant confirming that it is the specific binding of the
cAb-HuL6 that is responsible for the inhibition of the partial
unfolding event. The data from these various experiments, there-
fore, provide evidence that the formation of partly unstructured
species, resulting from the locally cooperative unfolding of the
b-domain and the C-helix is the critical event that triggers the
aggregation process in the absence of the antibody fragment.
Moreover, the results show that binding to the antibody fragment
not only increases the overall stability of the D67H variant to a value
even greater than that of the wild-type protein, but also reverses the
loss of global structural cooperativity that results from the
mutation.
To investigate in greater detail the structural basis for the efficacy
of the antibody fragment as an inhibitor of the formation of amyloid
fibrils, the complex with wild-type lysozyme was crystallized and the
structure solved at a resolution of 1.8 Å by using X-ray diffraction
(Fig. 3). Comparison of this structure with those available for
unbound lysozyme reveals that no significant conformational
changes result from the complexation of the protein to the antibody
fragment; the Ca r.m.s. deviations of the lysozyme molecule in the
complex from that of the uncomplexed species (pdb entries 1LZ1,
1REX and 1JWR) are all less than 0.4 Å. The structure of the
complex reveals that the epitope consists of 14 residues of the
lysozyme molecule and encompasses residues located in the loop
between the A and B helices in the a-domain (L15, G16, Y20), in the
long loop within the b-domain (A76, C77, H78, L79) and in the
C-helix (A90, D91, A94, C95, K97, R 98, R101) (Fig. 3); binding of
the antibody fragment results in a surface coverage in these regions
of about 100 Å2, 165 Å2 and 305 Å2, respectively. Thus, the C-helix
contributes about half of the total surface area of the enzyme that is
bound to the antibody fragment.
We performed NMR experiments to characterize further the
interaction in solution between the wild-type and variant lysozyme
molecules and the antibody fragment. Comparison of the 15N-1H
heteronuclear single quantum coherence (HSQC) NMR spectra of
the unbound proteins, uniformly labelled with 15N, with spectra of
the proteins complexed to an unlabelled antibody fragment allowed
the binding region to be probed in a site-specific manner by analysis
of the chemical shift perturbations of the resonances of the amide
groups of individual residues. This analysis reveals that the reson-
ances of approximately the same number of residues in the spectra
of the wild-type lysozyme and the D67H variant (31 and 29,
respectively) exhibit a significant chemical shift perturbation
upon binding to the antibody fragment in solution (Fig. 4).
Resonances of all the lysozyme residues found to be in direct contact
with the antibody fragment in the X-ray structure were observed to
be significantly shifted relative to their positions in the uncom-
plexed protein. Most of the additional residues with perturbed
chemical shifts are located in close proximity to those that are in
direct contact with the antibody fragment. Moreover, it is evident
that the epitope is essentially identical in the D67H variant as in
wild-type lysozyme. This last finding is consistent with the very
Figure 4 Chemical shift perturbations induced by the binding of the cAb-HuL6 to wild-
type lysozyme (a) and the D67H variant (b). The pink and blue bars indicate the chemical
shift perturbations of the 1H and 15N resonance, respectively; residues experiencing a
chemical shift change of not less than ^0.4 p.p.m. for 15N or not less than ^0.1 p.p.m.
for 1H resonances are considered to be significantly affected by the binding of the antibody
fragment. The Ca atoms of these residues are shown in a blue space-filling
representation on the ribbon diagram (c, wild-type lysozyme; d, D67H variant). The peaks
corresponding to residues 76, 78 and 79 in the D67H-cAbHuL6 complex and to residue
78 in the wild-type protein complex have not been assigned; therefore shift differences for
these peaks are not shown in the histograms. No unassigned peaks are visible in the
spectra of either complex within 0.1 p.p.m. (1H) and 0.4 p.p.m. (15N) of the peak positions
of residue 78 in the spectra of the unbound proteins. This finding strongly suggests that
large shift perturbations are observed for this residue in both complexes. In d, the region
of the D67H molecule that has been found to unfold transiently in a locally cooperative
manner11 is coloured yellow, and the amyloidogenic mutation D67H is indicated in green.
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similar values of the dissociation constants for binding of the
antibody fragment to wild-type lysozyme (K D ¼ 0.7 nM (ref. 7))
and the D67H variant (K D ¼ 1.2 nM, this work).
The crystal structure of the complex indicates that the antibody
fragment binds to the C-terminal region of the long loop of the
b-domain and to the C-helix of the a-domain of lysozyme.
Remarkably, these are two of the elements of secondary structure
that are destabilized by the D67H amyloidogenic mutation as a
result of the disruption of the interface between the a- and
b-domains10,11 (Fig. 4d). This result therefore provides a ready
explanation for the ability of the antibody fragment to prevent
the partial unfolding and subsequent aggregation of the D67H
variant. More detailed analysis, however, reveals that only 11 of the
nearly 60 residues involved in the transient unfolding of the D67H
variant are in direct contact with the antibody fragment. Thus, the
effects of binding are not simply to mask the entire region of the
protein destabilized by the mutation and hence to prevent its
unfolding from the remainder of the structure. Rather, it appears
that the binding of the antibody fragment restores the global
cooperativity of the lysozyme structure that is disrupted by the
D67H mutation by a more subtle mechanism. It is therefore of
particular interest that perturbations to the NMR chemical shifts,
reflecting small changes in the protein structure, include the amide
resonances of residues 56 and 57, both of which are far from the site
of mutation and from the binding interface with the antibody. In the
crystal structure of the D67H variant it was found that the mutation
disrupts the hydrogen bond network present in the b-domain of the
wild-type protein, and that the resulting small conformational
changes are transmitted to the region of the structure where residue
56 is located10. Moreover, residues 56 and 57 are themselves the
locations of two of the other well-defined pathogenic mutations of
lysozyme that give rise to amyloid disease4,6.
As the result of the increasingly serious impact of amyloid
diseases such as Alzheimer’s and Parkinson’s on the ageing popu-
lations of the developed world, a wide range of strategies for the
prevention or treatment of these diseases is being very actively
explored20–24. One of the most attractive therapeutic options is to
prevent the accumulation of aggregation-prone species by inhibit-
ing the processes that lead to their formation23. Studies of transthy-
retin, for example, have shown that small molecules mimicking the
binding of natural ligands are highly promising therapeutic agents
because they stabilize the native state of the protein, in this case a
tetramer, by binding at the interface between the subunits and
preventing their dissociation under physiological conditions25,26.
We have shown here that a specific antibody fragment can achieve a
similar effect in reducing the concentration of a partly unfolded
aggregation-prone species, but in this case by stabilizing the
interactions between distinct sub-structures of a monomeric pro-
tein. Unlike the situation with transthyretin, stabilization and
inhibition of lysozyme aggregation does not occur as a result of
binding at a site that is normally occupied by a natural ligand.
Rather, it occurs through the restoration of the global cooperativity
of the native structure, disrupted by the amyloidogenic mutation
that is a consequence of the binding interaction. The region of the
protein surface that forms the epitope of the antibody fragment
does not include the site of the disruptive mutation; the antibody
fragment thus acts through transmitted conformational changes in
a manner that is in some respect analogous to the way in which
binding of an effector molecule can regulate an allosteric protein27.
This suggests that exploration of a series of antibodies raised against
a given protein antigen could well allow the discovery of species able
to overcome the effects of a wide range of pathogenic mutations, or
indeed to stabilize a wild-type protein without disruption of the
binding site or sites that are essential to its function. The properties
of single domain fragments of camelid antibodies may make
humanized versions of these molecules particularly favourable for
such a purpose9. A
Methods
Proteins
Wild-type human lysozyme and its D67H variant, including uniformly [15N]proteins,
cAb-R2 and the cAb-HuL6 were expressed and purified as described previously7,28. The
affinity of cAb-HuL6 for the two forms of lysozyme was determined by using surface
plasmon resonance7.
Thermal unfolding monitored by circular dichroism and fluorescence
measurements
Thermal unfolding experiments were done in 0.1 M citrate buffer pH 5.5 containing 3 M
urea, by raising the temperature from 5 to 75–95 8C at a rate of 0.5 8C min21. The far
ultraviolet circular dichroism signal was monitored at 228 nm by using a Jasco J-810
spectropolarimeter with a 0.1-cm path-length cell using lysozyme concentrations of
13.5 mM. At this wavelength the signal arising from the antibody fragment is very low
compared with that of lysozyme7. The changes in signal amplitude as a result of unfolding
of the antibody fragment are therefore negligible, making it possible to monitor
specifically the unfolding of lysozyme in the presence of cAb-HuL6. ANS-binding
fluorescence emission data were recorded on a Cary Eclipse spectrofluorimeter. The
excitation and emission wavelengths were 350 nm and 475 nm, respectively, and the slit
widths were 5 nm. The lysozyme concentration was 2.5 mM in a 1-cm path-length cuvette
and the final ANS concentration was 160 mM. For the experiments in the presence of the
antibody fragment, equimolar amounts of cAb-HuL6 and D67H lysozyme were mixed
immediately before the experiment.
Aggregation monitored by right-angle light scattering
Stock solutions of the proteins were prepared from lyophilized material, passed through a
0.22 mm filter, diluted to the desired final concentration into 0.1 M citrate buffer pH 5.5
containing 3 M urea and incubated at 48 8C with stirring in a Cary Eclipse
spectrofluorimeter. The excitation wavelength was 500 nm and changes in fluorescence
emission were monitored at 500 nm with slit widths of 5 nm. Aliquots of the samples after
6 h of incubation were centrifuged for 15 min at 15,000 g. Pellets were resuspended in 50 ml
of water and used for X-ray diffraction measurements. The supernatant was passed
through a 0.22 mm filter and its protein concentration was analysed by SDS–PAGE
(NuPAGE, 4–12% Bis-Tris, Invitrogen) and the bicinchoninic acid (BCA) assay (Pierce).
Congo red binding
Congo red binding assays were performed as described previously16 by using a Cary 4 UV–
Vis spectrophotometer.
Electron microscopy
Samples were applied to Formvar-coated nickel grids, stained with 2% (w/v) uranyl acetate
solution and viewed in a Phillips CEM100 transmission electron microscope operating at
80 kV.
X-ray fibre diffraction
Samples were prepared by air-drying fibril preparations between two waxed-filled capillary
ends, aligned in the X-ray beam. Diffraction images were collected with a Rigaku Cu Ka
rotating-anode source (wavelength 1.54 Å) and an R-Axis IV image-plate X-ray detector.
Mass spectrometry
Pulse labelling experiments, which involved the replacement of deuterium atoms with
hydrogen atoms from the solvent H2O, were done with D67H lysozyme that had initially
been deuterated at all the labile exchangeable sites and a Bio-Logic QFM5 mixer, as
described previously11. The samples that were allowed to exchange for more than 2 min
were prepared by manual mixing. For the experiments in the presence of an equimolar
amount of cAb-HuL6, deuterated D67H lysozyme and protonated cAb-HuL6 were mixed
immediately before the experiment was performed. Exchange was done at pH 8.0
(100 mM ammonia/formic acid in H2O) and 37 8C for various lengths of time and then
quenched by decreasing the temperature and pH. The samples were electrosprayed at the
base pressure of the Platform mass spectrometer (Micromass) and at a cone voltage of
150 V, where the complex between the antibody fragment and the lysozyme was found to
dissociate. Mass spectra shown in Fig. 2 represent the convolution of the þ8, þ9, þ10
charge states with minimal smoothing and converted to a mass scale.
Crystal structure determination
Crystals of cAb-HuL6 complexed with wild-type lysozyme were grown by the hanging
drop vapour diffusion method at 20 8C. Drops initially contained equal volumes of protein
(0.2 mM in buffer) and reservoir buffer (20% w/v PEG 4000 and 0.2 M imidazole malate,
pH 6.0). Details of the data collection and processing will be described elsewhere
(Decanniere et al., manuscript in preparation). The atomic coordinates have been
deposited in the Protein Data Bank (accession number 1OP9).
NMR spectroscopy
Two-dimensional gradient-enhanced 15N-1H HSQC spectra of unbound wild-type and
D67H lysozyme, and of the proteins complexed with cAb-HuL6, were collected at
750 MHz at 35 8C. The samples of the complexes were made up with ,0.6 and ,0.4 mM
15N-labelled wild-type and D67H lysozyme, respectively, and with a ,20% excess of
unlabelled cAb-HuL6, to ensure all the lysozyme was bound in the complex, at pH 6.5 in
20 mM phosphate buffer in 95% H2O/5% D2O. The HSQC spectra were collected with 64
transients per t1 increment, with 128 and 1024 complex points in t1 and t2, and with sweep
widths of 10,582 and 2,273 Hz in F 2 and F1. The
1H and 15N resonances of wild-type
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lysozyme in the complex were assigned by using a 15N-edited three-dimensional nuclear
Överhauser enhancement (NOE) spectroscopy—HSQC experiment. This was collected
with eight transients per increment, with 128, 28 and 512 complex points in t1 (
1H), t2
(15N) and t3 (
1H), and with acquisition times of 14.2, 12.3 and 48.4 ms in t1, t 2 and t3. The
observed NOE data for bound lysozyme were interpreted by using published assignments
for the free protein29. The resonances of D67H were assigned by comparison with the
assigned spectrum of the unbound protein11 and that of the wild-type complex.
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The systematic comparison of genomic sequences from different
organisms represents a central focus of contemporary genome
analysis. Comparative analyses of vertebrate sequences can
identify coding1–6 and conserved non-coding4,6,7 regions, includ-
ing regulatory elements8–10, and provide insight into the forces
that have rendered modern-day genomes6. As a complement to
whole-genome sequencing efforts3,5,6, we are sequencing and
comparing targeted genomic regions in multiple, evolutionarily
diverse vertebrates. Here we report the generation and analysis of
over 12 megabases (Mb) of sequence from 12 species, all derived
from the genomic region orthologous to a segment of about
1.8 Mb on human chromosome 7 containing ten genes, including
the gene mutated in cystic fibrosis. These sequences show con-
servation reflecting both functional constraints and the neutral
mutational events that shaped this genomic region. In particular,
we identify substantial numbers of conserved non-coding seg-
ments beyond those previously identified experimentally, most
of which are not detectable by pair-wise sequence comparisons
alone. Analysis of transposable element insertions highlights the
variation in genome dynamics among these species and confirms
the placement of rodents as a sister group to the primates.
The NIH Intramural Sequencing Center (NISC) Comparative
Sequencing Program aims to sequence and to analyse targeted
genomic regions in multiple vertebrates. Our initial target is a
genomic segment of about 1.8 Mb on human chromosome 7q31.3
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